Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 492.5
(6.9%)
INR 492.5
(6.9%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.55 Million INR | 44.38% |
| 2022 | 8.69 Million INR | -82.86% |
| 2021 | 50.73 Million INR | -20.78% |
| 2020 | 64.04 Million INR | 171.55% |
| 2019 | 23.58 Million INR | 11163.29% |
| 2018 | 209.39 Thousand INR | -85.23% |
| 2017 | 1.41 Million INR | -94.25% |
| 2016 | 24.63 Million INR | -29.91% |
| 2015 | 35.15 Million INR | -23.41% |
| 2014 | 45.89 Million INR | 2858.16% |
| 2013 | 1.55 Million INR | -4.8% |
| 2012 | 1.62 Million INR | -12.3% |
| 2011 | 1.85 Million INR | -78.7% |
| 2010 | 8.72 Million INR | -93.13% |
| 2009 | 127.04 Million INR | 44.82% |
| 2008 | 87.72 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 12.55 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 19.27 Million INR | 0.0% |
| 2023 FY | 12.55 Million INR | 44.38% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q2 | 9.43 Million INR | 0.0% |
| 2022 FY | 8.69 Million INR | -82.86% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 8.69 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 50.73 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 56.53 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 50.73 Million INR | -20.78% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 64.04 Million INR | 171.55% |
| 2020 Q4 | 64.04 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 71.28 Million INR | 0.0% |
| 2019 Q4 | 23.58 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 23.58 Million INR | 11163.29% |
| 2019 Q2 | 821 Thousand INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 795 Thousand INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 209.39 Thousand INR | -85.23% |
| 2018 Q4 | 209.39 Thousand INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 1.41 Million INR | 0.0% |
| 2017 FY | 1.41 Million INR | -94.25% |
| 2017 Q2 | 21.44 Million INR | 0.0% |
| 2016 Q2 | 29.79 Million INR | 0.0% |
| 2016 FY | 24.63 Million INR | -29.91% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 24.63 Million INR | 0.0% |
| 2015 Q2 | 41.95 Million INR | 0.0% |
| 2015 Q4 | 35.15 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 35.15 Million INR | -23.41% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 45.89 Million INR | 2858.16% |
| 2014 Q4 | 45.89 Million INR | 0.0% |
| 2014 Q2 | 1.2 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 1.55 Million INR | 0.0% |
| 2013 FY | 1.55 Million INR | -4.8% |
| 2013 Q2 | 1.1 Million INR | 0.0% |
| 2012 Q2 | 2.24 Million INR | 0.0% |
| 2012 FY | 1.62 Million INR | -12.3% |
| 2012 Q4 | 1.62 Million INR | 0.0% |
| 2011 FY | 1.85 Million INR | -78.7% |
| 2011 Q4 | 1.85 Million INR | 0.0% |
| 2010 FY | 8.72 Million INR | -93.13% |
| 2009 FY | 127.04 Million INR | 44.82% |
| 2008 FY | 87.72 Million INR | 0.0% |
| 2008 Q4 | 87.72 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 98.003% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.941% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 91.494% |
| Granules India Limited | 689.71 Million INR | 98.18% |
| Indoco Remedies Limited | 3.51 Billion INR | 99.643% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | 94.662% |
| Alkem Laboratories Limited | 400 Million INR | 96.861% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -252.174% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | 54.897% |
| Bajaj HealthCare Limited | 650.34 Million INR | 98.069% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 96.473% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 99.79% |
| Eris Lifesciences Limited | 6.54 Billion INR | 99.808% |
| FDC Limited | 2.46 Million INR | -409.124% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 99.172% |
| Gufic Biosciences Limited | 1.53 Billion INR | 99.185% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 88.753% |
| Ipca Laboratories Limited | 5.8 Billion INR | 99.784% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | 83.386% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 99.316% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 99.854% |
| Lupin Limited | 1.55 Billion INR | 99.191% |
| Mankind Pharma Limited | 248.67 Million INR | 94.951% |
| Medico Remedies Limited | 8.67 Million INR | -44.776% |
| Megasoft Limited | 1.35 Billion INR | 99.075% |
| NATCO Pharma Limited | 53 Million INR | 76.311% |
| Piramal Pharma Limited | 24.83 Billion INR | 99.949% |
| RPG Life Sciences Limited | -30.3 Million INR | 141.436% |
| Sigachi Industries Limited | 265.79 Million INR | 95.276% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | 5.602% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 94.088% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 1129.943% |
| Unichem Laboratories Limited | 382.22 Million INR | 96.715% |
| Wanbury Limited | 820 Million INR | 98.469% |
| Windlas Biotech Limited | 20.18 Million INR | 37.785% |
| ZIM Laboratories Limited | 356 Million INR | 96.473% |
| Zydus Lifesciences Limited | 251 Million INR | 94.998% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | 88.222% |
| Divi's Laboratories Limited | 20 Million INR | 37.225% |
| Hester Biosciences Limited | 1.81 Billion INR | 99.309% |
| Procter & Gamble Health Limited | 68.8 Million INR | 81.751% |
| Amrutanjan Health Care Limited | 13.96 Million INR | 10.116% |
| Bal Pharma Limited | 363.82 Million INR | 96.549% |
| Strides Pharma Science Limited | 6.71 Billion INR | 99.813% |
| Venus Remedies Limited | 386.8 Million INR | 96.754% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -3038.75% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 99.105% |
| Shilpa Medicare Limited | 5.6 Billion INR | 99.776% |
| Aarti Drugs Limited | 2.75 Billion INR | 99.544% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 99.876% |
| Valiant Laboratories Limited | 746.63 Million INR | 98.318% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 94.689% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | 98.814% |
| Themis Medicare Limited | 267.74 Million INR | 95.311% |
| Hikal Limited | 4.22 Billion INR | 99.703% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.922% |
| Sequent Scientific Limited | 1.42 Billion INR | 99.12% |
| Novartis India Limited | 50.7 Million INR | 75.237% |
| Wockhardt Limited | 8.91 Billion INR | 99.859% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.96% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | 97.205% |
| Morepen Laboratories Limited | 33.64 Million INR | 62.678% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 90.598% |